Last reviewed · How we verify
NCT04975477
CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102)
trial testing Esophagogasrtoduodendoscopy and liver stiffness in Compensated Advanced Chronic Liver Disease in 1,000 participants. Status unknown.
16 August 2021
Quick facts
| Lead sponsor | Hepatopancreatobiliary Surgery Institute of Gansu Province |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 16 July 2021 |
| Primary completion | 16 August 2021 |
| Estimated completion | 16 August 2021 |
| Sites | 7 locations across Japan, South Korea, China, Egypt, India |
Drugs / interventions tested
- Esophagogasrtoduodendoscopy and liver stiffness
- hepatic venous pressure gradient
Conditions studied
- Compensated Advanced Chronic Liver Disease — all drugs for Compensated Advanced Chronic Liver Disease →
Sponsor
Hepatopancreatobiliary Surgery Institute of Gansu Province
Who can join
18 and older, any sex, with Compensated Advanced Chronic Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Compensated advanced chronic liver disease (cACLD) was associated with a high rate of variceal bleeding, ascites, and hepatic encephalopathy due to portal hypertension. In these patients, esophagogastroduodenoscopy and hepatic venous pressure gradient were recommended methods to evaluate portal hypertension. However, non-invasive predictors of outcomes to stratify care remains needed. Although the updated EASL guideline has recommended that patients with liver stiffness \>20kPa or platelets \<150\*10\^9/L had the high risk of decompensation, the criteria remains to be validated. This international multicenter study aims to develop a novel CHESS-SAVE score to further predict the risk of liver decompensation in cACLD patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study.
Liu C, Cao Z, Yan H, Wong YJ, et al · · 2022 · cited 10× · PMID 35973168 · DOI 10.14309/ajg.0000000000001873
Verify or expand the search:
- PubMed search for NCT04975477
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hepatopancreatobiliary Surgery Institute of Gansu Province trials
Trials by the same sponsor.
- NCT03104569 — Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma · NA · not yet recruiting
- NCT07321431 — The Optimal Measurement Time for the New Gallbladder Function Assessment Method · NA · recruiting
- NCT07091526 — Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer · recruiting
- NCT07039864 — A Novel Strategy for Evaluating Gallbladder Contraction Function by Ultrasound · NA · completed
- NCT06697405 — Impact of Cardiopulmonary Bypass Time on Gastrointestinal Complications · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04975477 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hepatopancreatobiliary Surgery Institute of Gansu Province
- Last refreshed: 23 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04975477.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing